Zobrazeno 1 - 10
of 61
pro vyhledávání: '"Keith, Fay"'
Autor:
Laurie H. Sehn, Nancy L. Bartlett, Matthew Matasar, Stephen J. Schuster, Sarit Assouline, John Kuruvilla, Mazyar Shadman, Chan Cheah, Keith Fay, Matthew Ku, Loretta J. Nastoupil, Michael Wei, Shen Yin, Iris To, Nan Hu, Juliana Min, Elicia Penuel, Anton Belousov, Alexandre Coimbra, Skander Jemaa, Brendan Bender, David Turner, L. Elizabeth Budde
Publikováno v:
HemaSphere, Vol 7, p e36694eb (2023)
Externí odkaz:
https://doaj.org/article/0df5a358399145da83d67731e87be8a3
Autor:
Yandong Shen, Luke Coyle, Ian Kerridge, William Stevenson, Christopher Arthur, Naomi McKinlay, Keith Fay, Christopher Ward, Matthew Greenwood, Oliver Giles Best, Ann Solterbeck, Alexander Guminski, Stephen Shumack, Stephen P. Mulligan
Publikováno v:
eJHaem, Vol 3, Iss 1, Pp 129-138 (2022)
Abstract Chronic lymphocytic leukaemia (CLL) is invariably accompanied by some degree of immune failure, and CLL patients have a high rate of second primary malignancy (SPM) compared to the general population. We comprehensively documented the incide
Externí odkaz:
https://doaj.org/article/bfe51b01464c452490529972a47017e0
Autor:
Nancy L. Bartlett, Laurie H. Sehn, Matthew J. Matasar, Stephen J. Schuster, Sarit Assouline, Pratyush Giri, John Kuruvilla, Miguel Canales, Sascha Dietrich, Keith Fay, Matthew Ku, Loretta J. Nastoupil, Michael C. Wei, Shen Yin, Iris To, Huang Huang, Juliana Min, Elicia Penuel, L. Elizabeth Budde
Publikováno v:
Blood. 140:1467-1470
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::beaff3b801c397522379e775bb500c8e
https://doi.org/10.1182/blood-2022-157691
https://doi.org/10.1182/blood-2022-157691
Autor:
Xavier Brennan, Barbara Withers, Andrew Jabbour, Sam Milliken, Eugene Kotlyar, Keith Fay, David Ma, Kavitha Muthiah, Nada Hamad, Anthony Dodds, Nikki Bart, Anne Keogh, Chris Hayward, Peter Macdonald, John Moore
Publikováno v:
Internal Medicine Journal. 52:1826-1830
Cardiac light chain (AL) amyloidosis is a condition with a very poor prognosis. We report a retrospective analysis comparing the traditional melphalan and dexamethasone protocol with cyclophosphamide, bortezomib and dexamethasone in late-stage cardia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6afaaa5b255a0263650521f21b93010b
https://doi.org/10.1111/imj.15926
https://doi.org/10.1111/imj.15926
Autor:
Nancy L. Bartlett, Sarit Assouline, Pratyush Giri, Stephen J. Schuster, Chan Yoon Y Cheah, Matthew J Matasar, Gareth P. Gregory, Dok-Hyun Yoon, Mazyar Shadman, Keith Fay, Sung-Soo Yoon, Carlos Panizo, Ian W. Flinn, Anna Johnston, Francesc Bosch, Laurie H Sehn, Michael C. Wei, Shen Yin, Iris To, Chi-Chung Li, Huang Huang, Antonia Kwan, Elicia Penuel, elizabeth Elizabeth budde
Publikováno v:
Blood Advances.
As part of a phase 1/2 study, this single-arm expansion cohort established the efficacy and safety of mosunetuzumab monotherapy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) (received >=2 prior lines of therapy). In
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6ee4a623e0906433bf5945899b54c01a
https://doi.org/10.1182/bloodadvances.2022009260
https://doi.org/10.1182/bloodadvances.2022009260
Autor:
Richard Blennerhassett, Jad Othman, Amber Biscoe, David Kliman, Georgia Mills, Emily Blyth, Kenneth Micklethwaite, John Kwan, Ian Bilmon, Abir Bhattacharyya, Shyam Panicker, Keith Fay, Sam Milliken, David Ma, Nada Hamad, William Stevenson, Chris Arthur, John Moore, Matthew Greenwood, David Gottlieb, Ian Kerridge
Publikováno v:
Internal Medicine Journal.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4aa9c48e3c3d0d555c196c483b7f86aa
https://doi.org/10.1111/imj.16043
https://doi.org/10.1111/imj.16043
Autor:
Elizabeth L. Budde, Nancy L. Bartlett, Pratyush Giri, Stephen J. Schuster, Sarit Assouline, Sung-Soo Yoon, Keith Fay, Matthew J. Matasar, Norma C. Gutierrez, Paula Marlton, Martin Dreyling, Dok Hyun Yoon, Georg Hess, John Radford, Volker Wiebking, Shen Yin, Eva Cybulski, David C. Turner, Huang Huang, Mingzhu Zhou, Elicia Penuel, Michael C. Wei, Laurie H. Sehn
Publikováno v:
Blood. 140:3753-3755
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::916ac955c457d4b1282e7d9e07b9fbbb
https://doi.org/10.1182/blood-2022-157729
https://doi.org/10.1182/blood-2022-157729
Autor:
Mark Hertzberg, Maher K. Gandhi, Judith Trotman, Belinda Butcher, John Taper, Amanda Johnston, Devinder Gill, Shir-Jing Ho, Gavin Cull, Keith Fay, Geoff Chong, Andrew Grigg, Ian D. Lewis, Sam Milliken, William Renwick, Uwe Hahn, Robin Filshie, George Kannourakis, Anne-Marie Watson, Pauline Warburton, Andrew Wirth, John F. Seymour, Michael S. Hofman, Rodney J. Hicks
Publikováno v:
Haematologica, Vol 102, Iss 2 (2017)
In the treatment of diffuse large B-cell lymphoma, a persistently positive [18F]fluorodeoxyglucose positron emission tomography (PET) scan typically carries a poor prognosis. In this prospective multi-center phase II study, we sought to establish whe
Externí odkaz:
https://doaj.org/article/e5491b57b7b849d8b0c33b7f8a7661b1
Autor:
Lihua E Budde, Laurie H Sehn, Matthew Matasar, Stephen J Schuster, Sarit Assouline, Pratyush Giri, John Kuruvilla, Miguel Canales, Sascha Dietrich, Keith Fay, Matthew Ku, Loretta Nastoupil, Chan Yoon Cheah, Michael C Wei, Shen Yin, Chi-Chung Li, Huang Huang, Antonia Kwan, Elicia Penuel, Nancy L Bartlett
Publikováno v:
The Lancet. Oncology. 23(8)
Mosunetuzumab is a CD20 × CD3 T-cell-engaging bispecific monoclonal antibody that redirects T cells to eliminate malignant B cells. In a phase 1 study, mosunetuzumab was well tolerated and active in patients with relapsed or refractory B-cell lympho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e95348535c6c8ba4c15d39bc7d45af6e
https://pubmed.ncbi.nlm.nih.gov/35803285
https://pubmed.ncbi.nlm.nih.gov/35803285
Autor:
Hui-Peng Lee, Gregor Verhoef, Morton Coleman, David Belada, Keith Fay, Claudia Corrado, Wanying Zhao, Remy Gressin, Douglas J DeMarini, Amitkumar Mehta, Jia Li, René-Olivier Casasnovas, Javier Munoz
Publikováno v:
Leukemia & Lymphoma. 62:368-376
Parsaclisib, a potent, highly selective, next-generation PI3Kδ inhibitor, was evaluated as monotherapy in CITADEL-202 (NCT02998476), an open-label, multicenter, phase 2 study in patients with relapsed or refractory diffuse large B-cell lymphoma. Pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3eaf7c9bbaa22a343372ef6eb9cd82a
https://doi.org/10.1080/10428194.2020.1832660
https://doi.org/10.1080/10428194.2020.1832660